Cara Therapeutics (CARA) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing new chemical entities that target the kappa opioid receptor to address unmet medical needs in pain and pruritus. Founded in 2006 as a spin‐out from Memorial Sloan Kettering Cancer Center, the company has advanced a proprietary portfolio of small‐molecule agonists designed to deliver analgesic and antipruritic benefits without the side effects typically associated with traditional opioid therapies.

The company’s most advanced product, difelikefalin, is approved in the United States under the trade name KORSUVA for the treatment of moderate‐to‐severe pruritus in hemodialysis patients. Cara is conducting additional trials of difelikefalin in atopic dermatitis, chronic kidney disease–associated pruritus in non‐dialysis populations and other conditions. Beyond its lead asset, the company is evaluating next‐generation kappa opioid receptor agonists in preclinical and early clinical stages to expand its pipeline into broader indications in pain management.

Headquartered in Stamford, Connecticut, Cara has established strategic partnerships and licensing agreements to facilitate the global development and commercialization of its therapies. Collaborations with established pharmaceutical and specialty distributors support regulatory filings and market access across North America, Europe and select Asian markets. The company’s infrastructure integrates research, development and regulatory expertise to streamline the transition of candidates from laboratory to late‐stage clinical evaluation.

Cara Therapeutics is guided by an experienced executive team and board of directors with deep roots in biopharmaceutical research and development. The management team combines drug discovery, clinical operations and commercial strategy backgrounds, positioning the company to advance its pipeline toward potential approvals and to address significant patient needs in pruritus and pain worldwide.

Key Stats

• Today's Range: N/A
• 50-Day Range: $13.29 to $17.10
• 52-Week Range: N/A
• Volume: 237,144 shs
• Average Volume: 22,209 shs
• Market Capitalization: $24.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cara Therapeutics Stock Analysis - MarketRank™

Cara Therapeutics scored higher than 4% of companies evaluated by MarketBeat, and ranked 931st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cara Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CARA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cara Therapeutics does not currently pay a dividend.

Dividend Growth

Cara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.39

Short Interest

There is no current short interest data available for CARA.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Cara Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CARA Stock Analysis - Frequently Asked Questions

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its quarterly earnings data on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) EPS for the quarter, missing analysts' consensus estimates of ($9.72) by $3.60. The biopharmaceutical company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 367.97% and a negative net margin of 1,099.76%.

When did Cara Therapeutics' stock split?

Cara Therapeutics shares reverse split before market open on Wednesday, April 16th 2025.The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CARA
• CIK: 1346830
• Web: www.caratherapeutics.com
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$118.51 million
• Net Margins: -1,099.76%
• Pretax Margin: -1,099.76%
• Return on Equity: -367.97%
• Return on Assets: -107.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.77
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.58 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,574,000
• Free Float: 4,429,000
• Market Cap: $24.33 million
• Optionable: Optionable
• Beta: 0.41